<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01225913</url>
  </required_header>
  <id_info>
    <org_study_id>20070934A</org_study_id>
    <nct_id>NCT01225913</nct_id>
    <nct_alias>NCT01225900</nct_alias>
  </id_info>
  <brief_title>Mechanism(s) of Airflow Limitation During Exacerbation of Asthma</brief_title>
  <official_title>Evaluation of Mechanism(s)Limiting Expiratory Airflow in Chronic, Stable Asthmatics Who Are Non-smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gelb, Arthur F., M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gelb, Arthur F., M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the site and mechanisms responsible for expiratory
      airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to
      severe persistent expiratory airflow obstruction. Treatment will include inhaled
      corticosteroids and long acting beta2agonists. The investigators are interested in
      determining whether the large and/or small airways are the predominant site of airflow
      limitation. The investigators are also interested in determining whether intrinsic small
      airways obstruction and/or loss of lung elastic recoil is responsible for expiratory airflow
      limitation. The investigators are also interested to evaluate the role of varying doses of
      inhaled corticosteroids to suppress large and small airway inflammation using exhaled nitric
      oxide as surrogate markers of inflammation. For comparison purposes, spirometry and
      measurements of exhaled nitric oxide will also be obtained if possible during a naturally
      occurring exacerbation of asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In addition we will also obtain above studies in asthmatics during naturally occuring
      exacerbation of asthma and following treatment. If available, results of lung function
      studies including measurements of lung elastic recoil will be compared to pathologic analyses
      of formalin fixed, air inflated lungs obtained at autopsy in asthmatics who die from asthma
      related or non-asthma related death. This kind of lung structure-function study will provide
      potential mechanism(s) to explain the loss of lung elastic recoil in acute and chronic
      asthmatics who are non-smokers. We will also obtain voxel quantification of high resolution
      thin section CT of lung obtained without IV contrast. Also, we will use fiberoptic
      bronchoscopy to obtain optical coherence tomography in stable asthmatics with mild to
      moderate to severe expiratory airflow limitation to assess integrity of the lung parenchyma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>To Better Understand the Mechanism(s) of Airflow Limitation During Exacerbation of Asthma</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exhaled nitric oxide</measure>
    <time_frame>20-60 days</time_frame>
    <description>evaluate the role of inhaled corticosteroid on exhaled nitric oxide production in large airways and peripheral small airways/alveoli</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mechanism(s) of expiratory airflow limitation</measure>
    <time_frame>1 to 5 years</time_frame>
    <description>loss of lung elastic recoil vs intrinsic airway obstruction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of unsuspected emphysema by autopsy or explanted lung</measure>
    <time_frame>1-5 years</time_frame>
    <description>Analysis of lungs obtained at autopsy or explanted lung for extent of emphysema</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Asthma observational study arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Asthmatics in this arm may be on varying dose of inhaled fluticasone 100-500mcg/salmeterol 50mcg bid via Advair MDI or equivalent dose via Diskus bid or Symbicort (budesonide 80-160mcg/formoterol 4.5mcg bid)or Dulera 100-200mcg mometasone/5 mcg formoterol bid, tiotropium 18mcg capsule daily. This is an observational study and additional pharmacologic intervention may include antibiotic and tapering doses of corticosteroids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone/salmeterol in all asthmatics</intervention_name>
    <description>budesonide 80ug/formoterol 4.5ug, 2 inhalations bid X 20-60 days or fluticasone 100ug/salmeterol 50ug, 1 inhalation bid X 20-60 days</description>
    <arm_group_label>Asthma observational study arm</arm_group_label>
    <other_name>symbicort 80/4.5</other_name>
    <other_name>advair 100/50 or 250/50 or 500/50 bid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide/formoterol or fluticasone/salmeterol in all asthmatics</intervention_name>
    <description>budesonide 160ug/formoterol 4.5ug, 2 inhalations bid or fluticasone 250ug/salmeterol 50ug, 1 inhalations bid</description>
    <arm_group_label>Asthma observational study arm</arm_group_label>
    <other_name>symbicort 160/4.5</other_name>
    <other_name>advair 250/50</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current non-smoking (&lt;10 pack yr smoking history)

          -  Stable, treated asthmatics

          -  Age 10-80 yr

          -  post 180ug albuterol by MDI: FEV 1/FVC &lt; 70% and FEV 1 &lt;80% predicted

        Exclusion Criteria:

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur F Gelb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arthur F Gelb Medical Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arthur F Gelb, MD</last_name>
    <phone>562-633-2204</phone>
    <email>afgelb@msn.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arthur F Gelb Medical Corporation</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <zip>90712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arthur F Gelb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gelb AF, Zamel N. Unsuspected pseudophysiologic emphysema in chronic persistent asthma. Am J Respir Crit Care Med. 2000 Nov;162(5):1778-82.</citation>
    <PMID>11069812</PMID>
  </reference>
  <reference>
    <citation>Gelb AF, Licuanan J, Shinar CM, Zamel N. Unsuspected loss of lung elastic recoil in chronic persistent asthma. Chest. 2002 Mar;121(3):715-21.</citation>
    <PMID>11888951</PMID>
  </reference>
  <reference>
    <citation>Gelb AF, Gutierrez CA, Weisman IM, Newsom R, Taylor CF, Zamel N. Simplified detection of dynamic hyperinflation. Chest. 2004 Dec;126(6):1855-60.</citation>
    <PMID>15596684</PMID>
  </reference>
  <reference>
    <citation>Gelb AF, Flynn Taylor C, Shinar CM, Gutierrez C, Zamel N. Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics. Chest. 2006 Jun;129(6):1492-9.</citation>
    <PMID>16778266</PMID>
  </reference>
  <reference>
    <citation>Gelb AF, Taylor CF, Nussbaum E, Gutierrez C, Schein A, Shinar CM, Schein MJ, Epstein JD, Zamel N. Alveolar and airway sites of nitric oxide inflammation in treated asthma. Am J Respir Crit Care Med. 2004 Oct 1;170(7):737-41. Epub 2004 Jun 30.</citation>
    <PMID>15229098</PMID>
  </reference>
  <reference>
    <citation>Gelb AF, Zamel N, Krishnan A. Physiologic similarities and differences between asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2008 Jan;14(1):24-30. Review.</citation>
    <PMID>18043272</PMID>
  </reference>
  <results_reference>
    <citation>Gelb AF, Moridzadeh R, Singh DH, Fraser C, George SC. In moderate-to-severe asthma patients monitoring exhaled nitric oxide during exacerbation is not a good predictor of spirometric response to oral corticosteroid. J Allergy Clin Immunol. 2012 Jun;129(6):1491-8. doi: 10.1016/j.jaci.2012.03.036. Epub 2012 May 2.</citation>
    <PMID>22560478</PMID>
  </results_reference>
  <results_reference>
    <citation>Gelb AF, Yamamoto A, Mauad T, Kollin J, Schein MJ, Nadel JA. Unsuspected mild emphysema in nonsmoking patients with chronic asthma with persistent airway obstruction. J Allergy Clin Immunol. 2014 Jan;133(1):263-5.e1-3. doi: 10.1016/j.jaci.2013.09.045. Epub 2013 Nov 28. Erratum in: J Allergy Clin Immunol. 2014 Apr;133(4):1232.</citation>
    <PMID>24290280</PMID>
  </results_reference>
  <results_reference>
    <citation>Gelb AF, Singh DH, Moridzadeh R, Fraser C, Tran D, Verbanck S, George SC. Age-stratified comparison of large and peripheral airway/alveolar nitric oxide levels in children and young adults. J Allergy Clin Immunol. 2013 Nov;132(5):1222-4. doi: 10.1016/j.jaci.2013.05.045. Epub 2013 Aug 6.</citation>
    <PMID>23932460</PMID>
  </results_reference>
  <results_reference>
    <citation>Senhorini A, Ferreira DS, Shiang C, Silva LF, Dolhnikoff M, Gelb AF, Mauad T. Airway dimensions in fatal asthma and fatal COPD: overlap in older patients. COPD. 2013 Jun;10(3):348-56. doi: 10.3109/15412555.2012.752806. Epub 2013 Mar 28.</citation>
    <PMID>23537051</PMID>
  </results_reference>
  <results_reference>
    <citation>Gelb AF, Yamamoto A, Verbeken EK, Nadel JA. Unraveling the Pathophysiology of the Asthma-COPD Overlap Syndrome: Unsuspected Mild Centrilobular Emphysema Is Responsible for Loss of Lung Elastic Recoil in Never Smokers With Asthma With Persistent Expiratory Airflow Limitation. Chest. 2015 Aug;148(2):313-320. doi: 10.1378/chest.14-2483.</citation>
    <PMID>25950858</PMID>
  </results_reference>
  <results_reference>
    <citation>Gelb AF, Christenson SA, Nadel JA. Understanding the pathophysiology of the asthma-chronic obstructive pulmonary disease overlap syndrome. Curr Opin Pulm Med. 2016 Mar;22(2):100-5. doi: 10.1097/MCP.0000000000000236. Review.</citation>
    <PMID>26717511</PMID>
  </results_reference>
  <results_reference>
    <citation>Gelb AF, Nadel JA. Understanding the pathophysiology of the asthma-chronic obstructive pulmonary disease overlap syndrome. J Allergy Clin Immunol. 2015 Sep;136(3):553-5. doi: 10.1016/j.jaci.2015.06.013.</citation>
    <PMID>26343939</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 19, 2010</study_first_submitted>
  <study_first_submitted_qc>October 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2010</study_first_posted>
  <last_update_submitted>August 18, 2019</last_update_submitted>
  <last_update_submitted_qc>August 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gelb, Arthur F., M.D.</investigator_affiliation>
    <investigator_full_name>Arthur F Gelb MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>lung function</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone-Salmeterol Drug Combination</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

